Electromed, Inc. (AMEX: ELMD) is a Healthcare company (Medical - Devices) with a market capitalization of $189M. The Maz Rating grades it against the other companies in its sector.
Electromed, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $23.13, Electromed, Inc. trades at 16.0x trailing earnings, 2.5x sales and 3.7x book value, with an EV/EBITDA of 11.0. Over the last twelve months it generated about $76M of revenue and $12M of net income. It runs a gross margin of 79.0%, an operating margin of 19.5% and a net margin of 15.8%. It shows return on equity of 23.7%, return on invested capital of 21.4% and a free cash flow yield of 5.0%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 7.19. Over the past 52 weeks the share price ranged from $22.67 to $47.40, with a beta of 0.43.
Electromed, Inc. does not currently pay a dividend.
5 Wall Street analyst ratings cover the stock: 5 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy, muscular dystrophies, amyotrophic lateral sclerosis, and post-surgical complications; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. It markets its products to physicians, health care providers, and directly to patients. Electromed, Inc. was incorporated in 1992 and is headquartered in New Prague, Minnesota.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Electromed, Inc. (ELMD) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 6.70% / 30% · Interest income / Revenue 0.79% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 6.70% / 33% · Receivables / Mkt Cap (36m) 13.0% / 49% · Interest income / Revenue 0.79% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 6.70% / 33.33% · Receivables / Mkt Cap (24m) 13.0% / 33.33% · Interest income / Revenue 0.79% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 0.03% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 27.8% / 33.33% · Receivables / Avg Assets (4Q) 49.4% / 33.33% · Interest income / Revenue 0.79% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 26.0% / 33.33% · (Cash+Recv) / Total Assets 76.2% / 33.33% · Interest income / Revenue 0.79% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Electromed, Inc. (ELMD) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. Electromed, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 0.79% of each dividend: Electromed, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q1 2027). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.